Cancer - Bayer Healthcare Pharmacetuicals Inc.

Cancer

ClinicalTrials.gov:

NCT06345001

An open-label phase 1 imaging study to evaluate the biodistribution, dosimetry, safety and pharmacokinetics of BAY 3630942, a 89Zr-labeled monoclonal antibody, with a pre-infusion of BAY 3547922, a monoclonal antibody-chelator conjugate, in patients with hepatocellular carcinoma or other select solid tumors.

Drug

BAY 3630942 and BAY 3547922

Condition

Patients with hepatocellular carcinoma or other select solid tumors.